文献速递术前评估与围术期医学疼痛医学

基于去脂体重的全身利多卡因在减重手术中的镇痛效果:前瞻性随机双盲安慰剂对照单中心研究

Analgesic efficacy of systemic lidocaine using lean body mass based dosing regime versus placebo in bariatric surgery: a prospective, randomised, double-blind, placebo-controlled, single-centre study.
PubMed 文献 · Br J Anaesth · 2023-05-12

该研究纳入140例减重手术患者,随机接受基于去脂体重计算的利多卡因(1.5 mg/kg,去脂体重×1.28)或安慰剂,比较术后48小时疼痛评分及阿片类药物用量等指标。结果显示两组术后4小时内NRS>3的比例无差异(利多卡因组69% vs 安慰剂组63%,P=0.507),最大疼痛评分、阿片消耗、肠功能恢复、术后恶心呕吐发生率及住院时间均无差异。结论认为该剂量利多卡因未改善减重手术患者的术后镇痛或任何次要结局。

要点

  • 基于去脂体重给予利多卡因1.5 mg/kg(去脂体重×1.28)未减少减重手术患者术后4小时内NRS>3的比例。
  • 利多卡因组与安慰剂组在最大疼痛评分、阿片消耗、肠功能恢复、PONV及住院时间上均无差异。
  • 该研究提示此剂量利多卡因对减重手术患者术后镇痛无效。

核心结论

  • 基于去脂体重的利多卡因未改善减重手术患者术后疼痛评分、镇痛效果或任何次要结局。

研究设计与样本

  • 前瞻性、随机、双盲、安慰剂对照、单中心研究,共纳入140例减重手术患者,随机分为利多卡因组或安慰剂组,137例完成研究。

主要发现

  • 术后4小时内NRS>3的比例:利多卡因组47/68(69%) vs 安慰剂组44/69(63%),P=0.507;术后第1小时P=0.177,第2小时P=0.513,第3小时P=0.145,第4小时P=0.510。
  • 最大疼痛评分、阿片类药物消耗量、肠功能恢复、术后恶心呕吐发生率及住院时间均无差异。

关键数值与推荐

  • 利多卡因剂量为1.5 mg/kg(基于去脂体重×1.28),使用1%盐酸利多卡因静脉给药。
  • 主要结局为术后48小时内疼痛体验,次要结局包括阿片类药物用量、PONV、肠功能恢复及住院时间。

临床怎么用

  • 对于减重手术患者,按此方案使用利多卡因未显示镇痛获益,不推荐常规用于改善术后镇痛。

局限性

  • 单中心研究,样本量140例,可能限制结果外推性;未报告其他潜在混杂因素或亚组分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous lidocaine is used as an adjuvant analgesic agent in perioperative settings. It has been investigated in various patient populations and surgical interventions, but there are limited data on its efficacy, particularly for patients undergoing bariatric surgery. Obese patients are at high risk of postoperative respiratory complications and can be expected to benefit from anaesthetic techniques that minimise opioid administration. METHODS: We studied administration of lidocaine hydrochloride 1% i.v. to general anaesthesia at a dose of 1.5 mg kg-1 (lean body mass×1.28) or placebo in patients undergoing bariatric surgery. Subjects randomly assigned to each group were surveyed for 48 h after surgery for experienced pain (primary outcome), and administered opioids, postoperative nausea and vomiting (PONV), resumption of bowel function, and length of hospital stay (secondary outcomes). RESULTS: We recruited and randomised 140 subjects to either the lidocaine or placebo group; 137 completed the study. Subjects with pain numeric rating scale (NRS) >3 within the first 4 h postoperatively were similar in both groups (proportion of any NRS >3 within first 4 h lidocaine group: 47/68 (69%) vs placebo group: 44/69 (63%), P=0.507; within first h P=0.177, within second h P=0.513, within third h P=0.145, within fourth h P=0.510). There was no difference in maximal pain score, opioid consumption, recovery of bowel function, incidence of PONV, or length of hospital stay. CONCLUSIONS: Lidocaine does not improve postoperative pain scores, analgesia, or any secondary outcomes in patients undergoing bariatric surgery. CLINICAL TRIAL REGISTRATION: NCT03667001.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Yurttas T, Djurdjevic M, Schnider TW, et al. Analgesic efficacy of systemic lidocaine using lean body mass based dosing regime versus placebo in bariatric surgery: a prospective, randomised, double-blind, placebo-controlled, single-centre study. Br J Anaesth. 2023. PMID: 37183098. doi:10.1016/j.bja.2023.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。